Safety and efficacy of immune checkpoint inhibitors in patients with HBV/HCV infection and advanced-stage cancer: A systematic review

BACKGROUND: Cancer patients with hepatitis B or C virus (HBV/HCV) infection are commonly seen in clinical practice, however, the data of safety and efficacy of immune checkpoint inhibitors (ICIs) among them are sparse, because active HBV/HCV infected patients were generally excluded by clinical tria...

Descripción completa

Detalles Bibliográficos
Autores principales: Pu, Dan, Yin, Liyuan, Zhou, Yuwen, Li, Wen, Huang, Lin, Cai, Liang, Zhou, Qinghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2020
Materias:
5700
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004734/
https://www.ncbi.nlm.nih.gov/pubmed/32000444
http://dx.doi.org/10.1097/MD.0000000000019013

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7004734/
https://www.ncbi.nlm.nih.gov/pubmed/32000444
http://dx.doi.org/10.1097/MD.0000000000019013

Ejemplares similares